Status:
UNKNOWN
Effect of Daily Glucomannan in Overweight Patients
Lead Sponsor:
ProMedica Health System
Conditions:
Overweight
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Glucomannan is a dietary supplement that has been marketed for weight loss. There is some research that supports this claim but more research is necessary. This is research study is being conducted to...
Eligibility Criteria
Inclusion
- Patients ≥18 years old
- Overweight (BMI ≥ 25 kg/m2)
Exclusion
- Pregnant or nursing women
- Women of childbearing age will be excluded unless they are on some form of contraception
- Participation in any other formal or informal weight reduction program
- Currently enrolled in another weight loss study
- Currently enrolled in a weight loss program
- Active attempt to lose weight with diet and/or exercise within the last month
- Currently on one of the following medications known to cause weight loss:
- Alli/Xenical(orlistat)
- Adipex-P (phentermine)
- Bontril (phendimetrazine)
- Dexoxyn (methamphetamine)
- Didrex (benzphetamine)
- Tenuate (diethylpropion)
- Meridia (sibutramine)
- Byetta (exenatide) or Victoza (liraglutide)
- Stimulants
- Recently (within the last three months) started on any medication that may cause weight gain
- A diagnosis of heart failure
- Structural abnormalities of the esophagus or gut
- Previous GI surgery for weight reduction
- Inflammatory bowel or irritable bowel disease
- A life expectancy of \<6 months
- Allergy to glucomannan or any component of the placebo
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01485718
Start Date
October 1 2011
End Date
March 1 2012
Last Update
December 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
W.W. Knight Family Practice Center
Toledo, Ohio, United States, 43606